Manhattan Scientifics, Inc. (MHTX)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Manhattan Scientifics, Inc. (MHTX) with AI Score 46/100 (Weak). Manhattan Scientifics, Inc. is a technology incubator focused on developing and commercializing life-enhancing technologies in the fields of nano-technologies and nano-medicine. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Manhattan Scientifics, Inc. (MHTX) Healthcare & Pipeline Overview
Manhattan Scientifics, Inc. operates as a technology incubator specializing in nano-technologies and nano-medicine within the healthcare sector. The company focuses on the development and commercialization of life-enhancing technologies, primarily in the United States, facing competition from established medical device companies and other emerging technology firms.
Investment Thesis
Manhattan Scientifics, Inc. presents a high-risk, high-reward investment opportunity due to its focus on early-stage nano-technologies and nano-medicine. The company's success is contingent on its ability to successfully develop and commercialize its technologies, which face significant regulatory and market hurdles. With a market capitalization of $0.00B and a negative P/E ratio of -0.05, the company's valuation is highly speculative. Key value drivers include successful clinical trials and regulatory approvals for its nano-medicine technologies. Upcoming catalysts include potential partnerships and licensing agreements. Potential risks include the high beta of 9.94, indicating extreme volatility, and the challenges of operating in the competitive medical device industry.
Based on FMP financials and quantitative analysis
Key Highlights
- Manhattan Scientifics operates as a technology incubator, focusing on early-stage development of nano-technologies and nano-medicine.
- The company's market capitalization is $0.00B, reflecting its early stage and speculative nature.
- Manhattan Scientifics has a negative P/E ratio of -0.05, indicating it is not currently profitable.
- The company's beta is 9.94, suggesting very high volatility compared to the market.
- Manhattan Scientifics does not offer a dividend, typical for growth-focused companies in the technology sector.
Competitors & Peers
Strengths
- Focus on innovative nano-technologies and nano-medicine.
- Potential for high growth in emerging markets.
- Early-stage access to promising technologies.
Weaknesses
- Limited financial resources and small market capitalization.
- Dependence on successful development and commercialization of technologies.
- High risk associated with early-stage ventures.
Catalysts
- Upcoming: Potential partnerships with pharmaceutical companies for drug delivery systems.
- Upcoming: Progress in clinical trials for nano-medicine applications.
- Upcoming: Regulatory approvals for new medical devices.
- Ongoing: Continued research and development in nano-technologies.
- Ongoing: Efforts to secure government funding and grants.
Risks
- Potential: Failure to obtain regulatory approvals for its technologies.
- Potential: Intense competition from established medical device companies.
- Potential: Limited financial resources to support research and development.
- Ongoing: High volatility in stock price due to its small market capitalization.
- Ongoing: Dependence on successful commercialization of its technologies.
Growth Opportunities
- Advancements in Nano-Medicine: The global nano-medicine market is projected to reach billions of dollars by 2030, driven by the increasing demand for targeted drug delivery and personalized medicine. Manhattan Scientifics can capitalize on this trend by focusing on developing innovative nano-medicine solutions for chronic diseases and cancer treatment. Successful clinical trials and regulatory approvals could significantly increase the company's valuation and market share. The timeline for realizing this opportunity depends on the progress of ongoing research and development efforts and the speed of regulatory reviews.
- Strategic Partnerships and Licensing Agreements: Manhattan Scientifics can accelerate its growth by forming strategic partnerships with larger pharmaceutical and medical device companies. These partnerships can provide access to funding, expertise, and distribution channels. Licensing agreements for its nano-technology platforms can generate revenue and validate the company's technology. The timeline for securing these partnerships depends on the company's ability to demonstrate the value and potential of its technologies. This strategy is ongoing as the company seeks to expand its network and market reach.
- Expansion into New Therapeutic Areas: Manhattan Scientifics can expand its focus beyond its current areas of interest and explore new therapeutic applications for its nano-technologies. This could include developing solutions for neurological disorders, cardiovascular diseases, and infectious diseases. The market for these therapeutic areas is substantial, and successful expansion could significantly increase the company's growth potential. This expansion is a long-term opportunity that requires significant investment in research and development.
- Government Funding and Grants: Manhattan Scientifics can leverage government funding and grants to support its research and development efforts. Government agencies such as the National Institutes of Health (NIH) and the National Science Foundation (NSF) offer grants for innovative research in nano-technology and nano-medicine. Securing these grants can provide non-dilutive funding and validate the company's technology. The timeline for securing these grants depends on the company's ability to submit competitive proposals and meet the eligibility criteria.
- Intellectual Property Protection: Manhattan Scientifics can strengthen its competitive advantage by securing strong intellectual property protection for its technologies. This includes filing patents for its nano-materials, drug delivery systems, and manufacturing processes. Strong intellectual property protection can prevent competitors from copying its technologies and provide a barrier to entry. This is an ongoing effort as the company continues to innovate and develop new technologies.
Opportunities
- Strategic partnerships with larger pharmaceutical and medical device companies.
- Expansion into new therapeutic areas and applications.
- Government funding and grants for research and development.
Threats
- Intense competition from established medical device companies.
- Stringent regulatory requirements and lengthy approval processes.
- Potential for technology obsolescence and market disruption.
Competitive Advantages
- Proprietary nano-technology platforms.
- Expertise in nano-medicine and targeted drug delivery.
- Early-stage access to innovative technologies.
About MHTX
Manhattan Scientifics, Inc., established in 1992 and based in New York City, functions as a technology incubator dedicated to the advancement and commercialization of life-enhancing technologies. The company's primary focus lies within the realms of nano-technologies and nano-medicine, where it seeks to develop and bring to market innovative solutions for various healthcare challenges. Originally named Grand Enterprises, Inc., Manhattan Scientifics has evolved to concentrate on identifying, developing, and commercializing early-stage technologies with high growth potential. The company's business model revolves around investing in and nurturing promising technologies until they reach a stage where they can be either spun off into separate entities, licensed to larger corporations, or further developed in-house. Manhattan Scientifics operates primarily within the United States, targeting opportunities where nano-scale technologies can provide significant improvements in medical treatments, diagnostics, and other healthcare applications. The company's success hinges on its ability to identify and develop groundbreaking technologies, navigate the complex regulatory landscape of the medical device industry, and secure the necessary funding to bring these innovations to market.
What They Do
- Develops nano-technologies for medical applications.
- Focuses on nano-medicine for targeted drug delivery.
- Incubates early-stage technologies with high growth potential.
- Seeks to commercialize life-enhancing technologies.
- Invests in promising technologies until they are ready for market.
- Aims to improve medical treatments and diagnostics through innovation.
Business Model
- Invests in early-stage nano-technology and nano-medicine companies.
- Develops and commercializes innovative healthcare solutions.
- Generates revenue through licensing agreements and potential spin-offs.
Industry Context
Manhattan Scientifics operates within the medical device industry, which is characterized by rapid innovation, stringent regulatory requirements, and intense competition. The market for nano-medicine is still in its nascent stages but is projected to experience significant growth in the coming years, driven by advancements in nanotechnology and increasing demand for targeted drug delivery systems. The company competes with established medical device companies and other emerging technology firms. Success in this industry requires significant investment in research and development, strong intellectual property protection, and the ability to navigate the complex regulatory landscape.
Key Customers
- Pharmaceutical companies seeking innovative drug delivery systems.
- Medical device manufacturers looking to incorporate nano-technologies.
- Healthcare providers seeking advanced diagnostic and treatment tools.
Financials
Chart & Info
Manhattan Scientifics, Inc. (MHTX) stock price: Price data unavailable
Latest News
No recent news available for MHTX.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MHTX.
Price Targets
Wall Street price target analysis for MHTX.
MoonshotScore
What does this score mean?
The MoonshotScore rates MHTX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Emmanuel Tsoupanarias
CEO
Emmanuel Tsoupanarias serves as the CEO of Manhattan Scientifics, Inc. His background includes experience in managing and developing early-stage technology companies. He has a track record of identifying and nurturing promising technologies in the healthcare sector. His expertise lies in strategic planning, business development, and financial management. He is responsible for overseeing the company's operations, driving its growth strategy, and building relationships with key stakeholders.
Track Record: Under Emmanuel Tsoupanarias's leadership, Manhattan Scientifics has focused on advancing its nano-technology and nano-medicine initiatives. Key achievements include securing funding for research and development, forming strategic partnerships, and advancing the company's technology pipeline. He has also overseen the company's efforts to protect its intellectual property and navigate the regulatory landscape. His leadership is focused on driving innovation and creating long-term value for shareholders.
MHTX OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Manhattan Scientifics may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This tier often includes companies that are distressed, early-stage, or have chosen not to meet the listing requirements of higher tiers.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Potential for high price volatility due to low liquidity.
- Increased risk of fraud or manipulation.
- Limited regulatory oversight and investor protection.
- Difficulty in obtaining reliable information about the company.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with investing in OTC stocks.
- Consult with a qualified financial advisor.
- Check for any regulatory actions or investigations.
- Company has been in operation since 1992.
- Focus on developing innovative technologies in nano-medicine.
- CEO with experience in managing early-stage technology companies.
Manhattan Scientifics, Inc. Stock: Key Questions Answered
What does Manhattan Scientifics, Inc. do?
Manhattan Scientifics, Inc. operates as a technology incubator, focusing on the development and commercialization of life-enhancing technologies in the fields of nano-technologies and nano-medicine. The company invests in early-stage ventures, providing resources and expertise to bring innovative medical solutions to market. Its business model centers around identifying promising technologies, nurturing their development, and ultimately commercializing them through licensing agreements, spin-offs, or internal development efforts. The company aims to improve medical treatments and diagnostics through nano-scale innovations.
What do analysts say about MHTX stock?
As of 2026-03-16, there is no available analyst coverage for Manhattan Scientifics, Inc. (MHTX). The company's small market capitalization and OTC listing may contribute to the lack of analyst interest. Investors should conduct their own due diligence and consider the risks associated with investing in early-stage, thinly traded companies. Key valuation metrics, such as P/E ratio, are currently negative, reflecting the company's lack of profitability. Growth considerations include the potential for successful commercialization of its nano-technology and nano-medicine initiatives.
What are the main risks for MHTX?
Manhattan Scientifics, Inc. faces several key risks, including the challenges of developing and commercializing early-stage technologies in the highly regulated medical device industry. The company's limited financial resources and small market capitalization increase its vulnerability to market fluctuations and funding shortfalls. Competition from established medical device companies poses a significant threat. Additionally, the company's success depends on obtaining regulatory approvals for its technologies, which can be a lengthy and uncertain process. The high beta of 9.94 indicates extreme volatility, making the stock susceptible to significant price swings.
What are the key factors to evaluate for MHTX?
Manhattan Scientifics, Inc. (MHTX) currently holds an AI score of 46/100, indicating low score. Key strength: Focus on innovative nano-technologies and nano-medicine.. Primary risk to monitor: Potential: Failure to obtain regulatory approvals for its technologies.. This is not financial advice.
How frequently does MHTX data refresh on this page?
MHTX prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven MHTX's recent stock price performance?
Recent price movement in Manhattan Scientifics, Inc. (MHTX) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Focus on innovative nano-technologies and nano-medicine.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider MHTX overvalued or undervalued right now?
Determining whether Manhattan Scientifics, Inc. (MHTX) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying MHTX?
Before investing in Manhattan Scientifics, Inc. (MHTX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be limited and less reliable than exchange-listed data.